Observational studyFrontiers in immunology2018
Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Pediatric bronchiolitis disease severity is associated with immune checkpoint dysregulation.Pediatric research · 2026Article
- Role of mucosal chemokines in the development of tissue-resident CD4Frontiers in immunology · 2026Review
- The Path Towards Effective Long-Lasting Tissue-Targeted Prime/Pull/Keep Herpes Simplex Therapeutic Vaccines.Vaccines · 2025Review
- Host-virus interactions during infection with a wild-type ILTV strain or a glycoprotein G deletion mutant ILTV vaccine strain in anMicrobiology spectrum · 2025Article
- Herpes simplex keratitis: A brief clinical overview.World journal of virology · 2024Review
- High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4Frontiers in immunology · 2024Article
- The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.Biomedicines · 2022Review
- Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.Pharmaceutics · 2022Review
- Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.Cells · 2022Review
- Understanding LAG-3 Signaling.International journal of molecular sciences · 2021Review
- Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man.Frontiers in immunology · 2021Review
- LAG-3: from molecular functions to clinical applications.Journal for immunotherapy of cancer · 2020Review
- Unique molecular signatures of antiviral memory CD8Scientific reports · 2020Article
- Upregulation of Multiple CD8Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8Journal of virology · 2019Article
- Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4Journal of virology · 2019Article
- Factors Affecting the Tissue Damaging Consequences of Viral Infections.Frontiers in microbiology · 2019Review
- NLRP3, NLRP12, and IFI16 Inflammasomes Induction and Caspase-1 Activation Triggered by Virulent HSV-1 Strains Are Associated With Severe Corneal Inflammatory Herpetic Disease.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Soumyabrata RoyLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Pierre-Grégoire CoulonLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Ruchi SrivastavaLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Hawa VahedLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Grace J KimLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Sager S WaliaLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Taikun YamadaLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Mona A FouladiLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Vincent T LyLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, School of Medicine, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
University of California, Irvine · US
Funding
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1MTherapeutic Ocular HSV Vaccine in HLA Transgenic RabbitsR01EY019896 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2010 to 2025
$5.1MDeveloping a Multi-epitope Pan-Coronavirus VaccineR01AI158060 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2020 to 2024
$3.7MMucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4MMechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic DiseaseR01EY026103 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2016 to 2019
$1.5MBlockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular HerpeR01EY024618 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2014 to 2016
$1.2MImpact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464kLAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425kNCATS NIH HHS UL1 TR001414NEI NIH HHS R01 EY019896NEI NIH HHS R01 EY024618NEI NIH HHS R01 EY026103NIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI158060NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326
Abstract
Recurrent viral diseases often occur after the viruses evade the hosts' immune system, by inducing exhaustion of antiviral T cells. In the present study, we found that functionally exhausted herpes simplex virus type 1 (HSV-1) -specific CD8
Indexed as
AdultAgedAnimalsAntigens, CDCD8-Positive T-LymphocytesCorneaDisease Models, AnimalEpitopes, T-LymphocyteFemaleHerpes Simplex Virus VaccinesHerpesvirus 1, HumanHumansImmunodominant EpitopesKeratitis, HerpeticLymphocyte Activation Gene 3 ProteinMaleAntigens, CDEpitopes, T-LymphocyteHerpes Simplex Virus VaccinesImmunodominant EpitopesLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 Receptoranimal modelCD8+ T cellsherpes simplex type 1humansimmune check pointLAG-3recurrenttherapeutic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.